Ron Bentsur, Chairman & CEO, 10% Owner at Nuvectis Pharma, Inc. (NVCT), bought 350 shares at $17.41 ($6K) on 2023-06-07, disclosed to the SEC on 2023-06-08.
Open-market purchase of $6k NVCT by Chairman & CEO, 10% Owner. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade C.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $17.41 | 230 | $4K | 65.6% |
| 2 | $17.53 | 120 | $2K | 34.4% |
| Total | $17.45 avg | 350 | $6K | 100% |
| Filing → |
| NVCT | BUY | 2024-12-26 | $21K | — | Filing → |
| NVCT | BUY | 2024-11-18 | $98K | — | Filing → |
| NVCT | BUY | 2024-05-15 | $13K | — | Filing → |